AAIC 2025 Abstract·26 DecPrecision Medicine in Alzheimer’s Disease (AD): Observed Efficacy Treatment Effects from Blarcamesine Clinical AD TrialsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·26 DecA Patient‐Centric, Digital Multimodal Post‐Market Approval Continuous Monitoring of Drug Safety & Efficacy Platform for BlarcamesineAI & dataPaper
AAIC 2025 Abstract·26 DecPhase IIb/III ATTENTION‐AD Study: Over Three Years of Continuous Treatment with Oral Blarcamesine Continues to Significantly Benefit Early Alzheimer’s Disease PatientsTrial in peopleInterventionsPaper
AAIC 2025 Abstract·25 DecA Novel Linear B‐Spline Mixed Effect Model for Alzheimer’s Disease Clinical Study DataComputational studyAI & dataPaper